Abstract
Background: Therapeutic options to treat atopic dermatitis are limited. Leukocytes from atopic patients have an abnormally high activity of cyclic adenosine monophosphate (AMP)-phosphodiesterase (PDE), which can be normalized in vitro by PDE inhibitors. Cipamfylline is a new potent and selective inhibitor of PDE-4. Objectives: To compare the efficacy and safety of up to 14 days' topical treatment with cipamfylline (0.15%) cream with vehicle and with hydrocortisone 17-butyrate (0.1%) cream. Patient and methods: International, multicentre, prospective, randomized double-blind, left-right studies of cipamfylline vs. vehicle and cipamfylline vs. hydrocortisone 17-butyrate in adult patients with stable symmetrical atopic dermatitis on the arms. Results: Both cipamfylline and hydrocortisone 17-butyrate reduced the Total Severity Score significantly (P <0.001). The reduction with cipamfylline was significantly greater than that with vehicle (difference vehicle-cipamfylline 1.67 95% confidence interval (CI) 1.06, 2.28; P <0.001) and was significantly less than with hydrocortisone 17-butyrate (difference hydrocortisone-cipamfylline - 2.10 95% CI - 2.93, - 1.27; P <0.001). Investigator and patient assessments of the overall treatment response showed a similar picture. Conclusions: Cipamfylline cream is significantly more effective than vehicle, but significantly less effective than hydrocortisone 17-butyrate cream in the treatment of atopic dermatitis.
Original language | English |
---|---|
Pages (from-to) | 299-307 |
Number of pages | 8 |
Journal | British Journal of Dermatology |
Volume | 147 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2002 |
Keywords
- Atopic dermatitis
- Cipamfylline
- Hydrocortisone 17-butyrate